Merck Reports Phase 3 KEYNOTE-361 Results for Keytruda in Urothelial Carcinoma

Merck today announced results from the Phase 3 KEYNOTE-361 trial evaluating Keytruda (pembrolizumab) plus platinum-based chemotherapy or Keytruda alone versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma. While the trial did not meet its primary endpoints, the data provided insights into the role of immunotherapy in urothelial carcinoma.